ASCO 2009: What's New in Breast Cancer Therapy?
作者信息
Biganzoli Laura, Bonnefoi Hervé, Cardoso Fatima, Coleman Robert, Thürlimann Beat
机构信息
'Sandro Pitigliani' Medical Oncology Unit, Department of Oncology, Hospital of Prato, Tuscany Cancer Institute, Prato, Italy.
出版信息
Breast Care (Basel). 2009;4(4):268-271. doi: 10.1159/000230677. Epub 2009 Aug 14.
Abstract
摘要
相似文献
1
ASCO 2009: What's New in Breast Cancer Therapy?
Breast Care (Basel). 2009;4(4):268-271. doi: 10.1159/000230677. Epub 2009 Aug 14.
2
[What's new in 2009 about urothelial tumors? Live from EAU, AUA and ASCO, ASCO-GU].
Prog Urol. 2010 Mar;20 Suppl 1:S38-40. doi: 10.1016/S1166-7087(10)70024-5.
3
What's new in prostate cancer research? Highlights of GU-ASCO 2014.
Can Urol Assoc J. 2014 Mar;8(3-4 Suppl 2):S8-S12. doi: 10.5489/cuaj.2013.
4
What's new in renal cell cancer research? Highlights of GU-ASCO 2014.
Can Urol Assoc J. 2014 Mar;8(3-4 Suppl 2):S13-5. doi: 10.5489/cuaj.2014.
5
What's New in Prostate Cancer Research? Highlights of GU-ASCO 2015.
Can Urol Assoc J. 2015 May-Jun;9(5-6Suppl3):S148-53. doi: 10.5489/cuaj.2994.
6
What's new in breast pathology 2022: WHO 5th edition and biomarker updates.
J Pathol Transl Med. 2022 May;56(3):170-171. doi: 10.4132/jptm.2022.04.25. Epub 2022 May 15.
7
What's New in Renal Cell Cancer Research? Highlights of GU-ASCO 2015.
Can Urol Assoc J. 2015 May-Jun;9(5-6Suppl3):S154-5. doi: 10.5489/cuaj.2995.
8
A symposium: "What's old, what's new, and what's useful in carcinoma of the breast, colon, and uterine cervix".
J Tenn Med Assoc. 1972 Dec;65(12):1091-107.
9
What's New With ASCO.org ?
J Oncol Pract. 2006 Nov;2(6):312. doi: 10.1200/JOP.2006.2.6.312.
10
Dermatologic therapy--1960. What's new? and what's true of what's new?
Acta Derm Venereol. 1961;41:187-93.
本文引用的文献
1
RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer.
J Clin Oncol. 2011 Apr 1;29(10):1252-60. doi: 10.1200/JCO.2010.28.0982. Epub 2011 Mar 7.
2
Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.
N Engl J Med. 2009 Jul 9;361(2):123-34. doi: 10.1056/NEJMoa0900212. Epub 2009 Jun 24.
3
Endocrine therapy plus zoledronic acid in premenopausal breast cancer.
N Engl J Med. 2009 Feb 12;360(7):679-91. doi: 10.1056/NEJMoa0806285.
4
Antitumor effects of doxorubicin followed by zoledronic acid in a mouse model of breast cancer.
J Natl Cancer Inst. 2008 Aug 20;100(16):1167-78. doi: 10.1093/jnci/djn240. Epub 2008 Aug 11.
5
Adjuvant oral clodronate improves the overall survival of primary breast cancer patients with micrometastases to the bone marrow: a long-term follow-up.
Ann Oncol. 2008 Dec;19(12):2007-11. doi: 10.1093/annonc/mdn429. Epub 2008 Jul 29.
6
Oral bisphosphonates as adjuvant therapy for operable breast cancer.
Clin Cancer Res. 2006 Oct 15;12(20 Pt 2):6301s-6304s. doi: 10.1158/1078-0432.CCR-06-1211.
7
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy.
Nature. 2005 Apr 14;434(7035):917-21. doi: 10.1038/nature03445.
8
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase.
Nature. 2005 Apr 14;434(7035):913-7. doi: 10.1038/nature03443.
Zotero 插件